Acute Myeloid Leukemia News and Research

RSS
Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.
Aprea's AML treatment receives EMEA recommendation for orphan drug status

Aprea's AML treatment receives EMEA recommendation for orphan drug status

EntreMed's ENMD-2076 for AML receives FDA's orphan drug designation

EntreMed's ENMD-2076 for AML receives FDA's orphan drug designation

Meda publishes 2009 year-end report

Meda publishes 2009 year-end report

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

VIDAZA prolongs survival in AML patients

VIDAZA prolongs survival in AML patients

Leukemia cells rely on fatty acid metabolism to grow and evade cell death

Leukemia cells rely on fatty acid metabolism to grow and evade cell death

CytRx announces its plans to advance multiple oncology development programs in 2010

CytRx announces its plans to advance multiple oncology development programs in 2010

Gene variant predisposes humans to develop acute myeloid leukemia, says study

Gene variant predisposes humans to develop acute myeloid leukemia, says study

Vion Pharmaceuticals files SPA for Onrigin-LDAC combination Phase II/III trial

Vion Pharmaceuticals files SPA for Onrigin-LDAC combination Phase II/III trial

Older patients with acute myeloid leukemia may benefit from decitabine drug

Older patients with acute myeloid leukemia may benefit from decitabine drug

Meda receives exclusive rights to distribute AML drug in Europe and Asia

Meda receives exclusive rights to distribute AML drug in Europe and Asia

EpiCept, Meda enter into exclusive commercialization agreement for Ceplene

EpiCept, Meda enter into exclusive commercialization agreement for Ceplene

Epigenetic diagnosis and therapies, a new strategy for treating cancer

Epigenetic diagnosis and therapies, a new strategy for treating cancer

FDA evaluates Phase III randomized trial in acute myeloid leukemia

FDA evaluates Phase III randomized trial in acute myeloid leukemia

Vion Pharmaceuticals files for bankruptcy

Vion Pharmaceuticals files for bankruptcy

Ambit Biosciences and Astellas Pharma to jointly develop and commercialize FLT3 kinase inhibitors

Ambit Biosciences and Astellas Pharma to jointly develop and commercialize FLT3 kinase inhibitors

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Preclinical study of Arno Therapeutics' drug candidate AR-42 presented at ASH 2009

Italian patent issued for NPM1 to test patients with AML

Italian patent issued for NPM1 to test patients with AML

Update on new clinical developments and other initiatives related to Ceplene

Update on new clinical developments and other initiatives related to Ceplene

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.